Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BYD1
UPID:
RM13_HUMAN
Alternative names:
39S ribosomal protein L13, mitochondrial
Alternative UPACC:
Q9BYD1; B2R4R8; Q9UI04
Background:
The Large ribosomal subunit protein uL13m, also known as 39S ribosomal protein L13, mitochondrial, plays a crucial role in the mitochondrial ribosome. Its primary function is to ensure the proper synthesis of proteins within the mitochondria, which is vital for cellular energy production and overall cell health.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein uL13m could open doors to potential therapeutic strategies. Its pivotal role in protein synthesis within mitochondria suggests that targeting this protein could lead to breakthroughs in treating diseases related to mitochondrial dysfunction.